Related Experiment Video

Updated: Oct 2, 2025

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model
08:22

In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model

Published on: October 27, 2020

3.1K

Hypothermia for Cardioprotection in Patients with St-Elevation Myocardial Infarction: Do Not Give It the Cold

Mohamed El Farissi1, Thomas P Mast1, Mileen R D van de Kar1

  • 1Department of Cardiology, Catharina Hospital, 5623 EJ Eindhoven, The Netherlands.

Journal of Clinical Medicine
|February 25, 2022
PubMed

Insights

Reperfusion therapy for ST-elevation myocardial infarction (STEMI) can paradoxically worsen heart damage. This review explores hypothermia as a potential treatment for myocardial reperfusion injury, examining past failures and future possibilities.

Area of Science:

  • Cardiology
  • Cardiovascular Research
  • Regenerative Medicine

Background:

  • ST-elevation myocardial infarction (STEMI) requires timely revascularization.
  • Reperfusion can cause additional damage, known as myocardial reperfusion injury.
  • Effective treatments for myocardial reperfusion injury are currently lacking.

Purpose of the Study:

  • To review hypothermia as a potential therapy for myocardial reperfusion injury in STEMI patients.
  • To discuss lessons learned from previous clinical trials of hypothermia.
  • To explore advanced hypothermic techniques and future directions for cardioprotection.

Main Methods:

  • Review of existing literature on myocardial reperfusion injury and hypothermia.
  • Analysis of preclinical and clinical trial data.
  • Discussion of current and emerging hypothermic treatment strategies.

Main Results:

  • Numerous experimental therapies, including hypothermia, have shown promise preclinically but failed in human trials.
  • Previous randomized controlled trials investigating hypothermia for STEMI have yielded negative results.
  • There is a significant gap between preclinical efficacy and clinical translation for cardioprotective strategies.

Conclusions:

  • Hypothermia has not yet proven effective in large-scale human trials for myocardial reperfusion injury in STEMI.
  • Further research is needed to understand the limitations of previous hypothermia trials.
  • Advanced techniques and a refined understanding of hypothermia may offer future cardioprotective benefits in STEMI.

Keywords:
PCISTEMIacute myocardial infarctionhypothermiamyocardial reperfusion injury

More Related Videos

Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management06:43

Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management

Published on: November 21, 2017

24.5K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

Related Concept Videos

Decreased Body Temperature01:29

Decreased Body Temperature

A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by...
728
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
97
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
27
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
44
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
78
Methods of reducing fever01:22

Methods of reducing fever

The signs and symptoms of fever include hot and dry skin, flushed face, thirst, muscle aches, anorexia, headache, tachycardia, tachypnea, and fatigue. Elevated body temperature is reduced using two methods: pharmacological and nonpharmacological. Proper identification and treatment of the root cause of a fever is of utmost importance.
Pharmacological Methods of Reducing Fever:
809